CompletedNCT00140192
Creatine Treatment in Psychiatric Disorders
Medication studyAges 18–60IsraelSchizophrenia
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- BeershevaSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateSeptember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- Beersheva Mental Health Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Israel
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00140192
- Official title
Show the full official title
Creatine as a New Treatment for Schizophrenia:A Double-Blind Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Beersheva
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Beersheva Mental Health Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including creatine.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
